Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2019
Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04258397 (Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease), which is not on this map. Cited by 64 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease (TOP-CKD)
Who cites it
64 citing papers in PubMed, 4 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis.Diabetes & metabolism journal · 2024Pooled it
- Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Pooled it
- Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients.Renal failure · 2021Pooled it
- Pooled it
- Plasma Biomarkers of Kidney Tubule Health during Ambulatory AKI and Kidney Function Recovery in SPRINT.Clinical journal of the American Society of Nephrology : CJASN · 2026Trial
- Trial
- Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Trial
- Trial
- Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.The New England journal of medicine · 2021Trial
- Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.Nephrology (Carlton, Vic.) · 2021Trial
- Dietary sodium restriction decreases urinary NGAL in older adults with moderately elevated systolic blood pressure free from chronic kidney disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Trial
- Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants.American journal of nephrology · 2020Trial
- Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Trial
- Association of Kidney Tubule Dysfunction and Injury Biomarkers With Long-term Risk of Acute Kidney Injury During Acute Congestive Heart Failure Hospitalizations.Kidney medicine · 2026Article
- Effects of intensive blood pressure control on cardio-kidney outcomes by KDIGO risk categories: a Post Hoc analysis of ACCORD-BP and SPRINT trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- The impacts of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on rates of acute kidney injury in hospitalized adults receiving multiple nephrotoxins.BMC nephrology · 2026Article
- Genetic screens of imaging-derived kidney volumes identify genes linked to kidney function.Kidney international · 2026Article
- Article
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- SubgroupTE: Advancing Treatment Effect Estimation with Subgroup Identification.ACM transactions on intelligent systems and technology · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundRandom assignment to the intensive systolic blood pressure (SBP) arm (<120mmHg) in the Systolic Blood Pressure Intervention Trial (SPRINT) resulted in more rapid declines in estimated glomerular filtration rates (eGFRs) than in the standard arm (SBP<140mmHg). Whether this change reflects hemodynamic effects or accelerated intrinsic kidney damage is unknown. STUDY
designLongitudinal subgroup analysis of clinical trial participants. SETTINGS &
participantsRandom sample of SPRINT participants with prevalent chronic kidney disease (CKD) defined as eGFR<60mL/min/1.73m OUTCOMES & MEASUREMENTS: Urine biomarkers of tubule function (β
results978 SPRINT participants (519 in the intensive and 459 in the standard arm) with prevalent CKD were included. Mean age was 72±9 years and eGFR was 46.1±9.4mL/min/1.73m LIMITATIONS: Exclusion of persons with diabetes, and few participants had advanced CKD.
conclusionsAmong participants with CKD in SPRINT, random assignment to the intensive SBP arm did not increase any levels of 8 urine biomarkers of tubule cell damage despite loss of eGFR. These findings support the hypothesis that eGFR declines in the intensive arm of SPRINT predominantly reflect hemodynamic changes rather than intrinsic damage to kidney tubule cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.